CION Ameerpet
If your report says borderline ovarian tumour — or tumour of low malignant potential, which is the same diagnosis under an older name — start with this. It is not invasive ovarian cancer, and chemotherapy has no established role in treating it. What it does need is complete surgical staging and patient, long-term follow-up, because these tumours can return years after they were removed.
A borderline ovarian tumour is an epithelial tumour of the ovary that has stopped behaving like a benign cyst but has not started behaving like a cancer. Down a microscope, the cells lining it have multiplied into several layers instead of one, they look abnormal, and they throw out delicate papillary tufts. What the pathologist does not see is destructive invasion into the ovarian tissue underneath. That absence is the whole definition.
Older reports call the same thing a tumour of low malignant potential, and some pathologists write atypical proliferative tumour. These are three names for one diagnosis, not three grades of severity. If your report uses one term and your surgeon uses another, nothing has changed between the two conversations.
Borderline tumours account for something like a tenth to a seventh of all epithelial ovarian tumours in published series, and they are found in considerably younger women than invasive ovarian cancer — often in the thirties and forties, sometimes in the twenties. Most are confined to one ovary at diagnosis, and a good number are picked up by accident, on a scan ordered for something else entirely.
Almost everything written for a general audience about ovarian cancer was written about invasive disease, and applying it here will frighten you for no reason. Borderline tumours are treated with surgery. Chemotherapy has no established role. The outlook after complete removal is very good. The two things that genuinely need your attention are whether the staging was complete, and whether the follow-up is long enough.
Benign, borderline and malignant are separated by one question: do the cells invade the ovarian stroma destructively? In a borderline tumour they do not, however abnormal they look.
Serous and mucinous account for the large majority. Serous tumours involve both ovaries fairly often; mucinous ones are usually single, one-sided and can grow very large, like their invasive mucinous counterparts.
Most borderline tumours appear during the reproductive years and most are stage I when found. That combination is why fertility-sparing surgery is a routine part of this conversation rather than a rare exception.
A borderline tumour is defined by what the pathologist does not see. The cells pile up in layers, look atypical and form papillary tufts — but there is no destructive invasion of the ovarian stroma. That single absence is why chemotherapy has no established role in this disease. The 5th edition of the WHO classification tightened the definition further: deposits outside the ovary that used to be called “invasive implants” of a serous borderline tumour are now classified and managed as low-grade serous carcinoma, while non-invasive implants remain borderline disease. If your report was issued before that change, its wording may not match the language your team uses now — which is one good reason to have an older report re-read. Source: WHO Classification of Tumours — Female Genital Tumours, 5th edition (2020); NCCN Ovarian Cancer guidelines.
The middle column is you. The columns on either side are what people mean when they say “just a cyst” or “ovarian cancer”, and neither description fits a borderline tumour honestly.
| Feature | Benign cystadenoma | Borderline tumour | Invasive ovarian carcinoma |
|---|---|---|---|
| Under the microscope | An orderly single layer of cells lining the cyst, without atypia | Cells piled into layers with atypia and papillary tufts, but no destructive invasion | Cells invading destructively into the ovarian stroma and beyond it |
| Typical age at diagnosis | Any age | Usually the thirties to the fifties | Usually after 60 for the commonest subtype |
| Stage when found | Confined to the ovary | Most often stage I, confined to one ovary | Most often stage III or IV for high-grade serous disease |
| Main treatment | Removal of the cyst | Removal with complete surgical staging | Staging and debulking surgery, then chemotherapy |
| Chemotherapy | Not used | No established role, at any stage | Central to treatment for most subtypes |
| Fertility-sparing surgery | Routine | An established option in early disease, decided before the operation | Possible only in selected early cases |
| Follow-up | None needed once removed | Long — recurrence can appear five, ten or more years later | Intensive in the early years, then tapering |
| Usual outcome | Cured by removal | Very good; most women are cured by surgery alone | Depends heavily on stage, subtype and completeness of surgery |
*Comparison drawn from the WHO classification of female genital tumours and NCCN ovarian cancer guidelines. Your own pathology report is the authority on your case — bring it to your consultation.
None of these is a sign that something is wrong. Each is a line in the pathology or operation report that changes what happens next, and each is routinely left unexplained because the headline answer — not invasive cancer — sounds like the end of the conversation.
Washings, omental sampling and peritoneal biopsies, or only the ovary removed? This one answer decides how confident anyone can be that the disease was confined.
The two behave differently in follow-up, in how often the other ovary is involved, and in whether the appendix needed attention during surgery.
A recognised variant of serous borderline tumour, more often bilateral and more often found with implants. It changes surveillance, not the diagnosis.
Small foci of invasion below the size threshold. It keeps the tumour borderline rather than making it a carcinoma, but it is worth knowing and discussing.
Non-invasive implants remain borderline disease. Deposits reported as invasive are now classified as low-grade serous carcinoma and managed as such.
Recurrence can appear many years later. A discharge at two or three years is early for this diagnosis, and worth questioning politely.
Take the pathology report and the operation notes to every appointment, and ask for a copy if you do not have one. In a diagnosis this dependent on wording, the documents answer questions that memory cannot.
Subtype, growth pattern, microinvasion, implants, and whether staging was complete. Those five lines decide whether you need anything more than follow-up — and they are worth 45 minutes of a specialist's time before anyone plans further surgery.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
The first consultation is free and no referral is needed. Bring your pathology report, operation notes and scans — most of the useful work happens in that conversation.
Six phrases do most of the work in these reports, and each one shifts the plan. This is what they mean in plain language, and why your team keeps returning to them.
The commonest type. It arises from cells resembling the lining of the fallopian tube, and forms a cyst with delicate branching papillae growing from its wall. Serous borderline tumours involve both ovaries appreciably more often than mucinous ones do, which is why the second ovary is examined carefully during surgery even when it looked normal on the scan.
They are also the type that can produce implants — deposits of similar tissue on the peritoneum lining the abdomen. Most implants are non-invasive and remain borderline disease. Their existence is the reason peritoneal biopsies and washings are part of proper staging rather than an optional extra.
The other common type, made of mucin-producing cells that resemble the lining of the gut or the cervix. Mucinous borderline tumours are usually one-sided and can become very large — large enough to fill the pelvis and abdomen — without having spread anywhere at all. Size in this tumour is a feature of the type, not a measure of how advanced it is.
Because a mucinous tumour sitting in an ovary can also have arrived from the appendix or bowel, the appendix is inspected during surgery and removed if it looks abnormal, and the gut is assessed where the picture warrants it. The same reasoning applies more forcefully to invasive mucinous ovarian carcinoma, where proving an ovarian origin is the first task of the entire work-up.
A recognised variant of serous borderline tumour in which the papillae become long, thin and repetitive, or the cells form a sieve-like pattern. Pathologists apply a size threshold before using the term, so it describes a substantial area of the tumour rather than an isolated focus.
It matters because tumours with this pattern are more often bilateral, more often found alongside implants, and more often recur. It does not turn a borderline tumour into a carcinoma, and it does not by itself mean chemotherapy. What it changes is how thoroughly the abdomen is staged and how closely you are followed afterwards.
Small foci where cells appear to have invaded the ovarian stroma, but which fall below the size threshold that would make the tumour a carcinoma. The report may describe them in millimetres or in square millimetres. The diagnosis remains a borderline tumour.
Microinvasion is reported more often in tumours found during pregnancy, and in most published series it has not been shown to change the outlook meaningfully on its own. It is nonetheless a phrase worth raising with your team, because it is one of the findings that tips a borderline case towards closer surveillance rather than routine follow-up.
Implants are deposits of tumour-like tissue found on the peritoneum, the omentum or the surface of other pelvic organs, and they are what turns a stage I borderline tumour into a higher stage. The report classifies them as non-invasive or invasive, and that word carries more weight than almost anything else in the document.
Non-invasive implants remain borderline disease and are managed as such. Deposits reported as invasive are now classified as low-grade serous carcinoma under the current WHO classification, and are staged, treated and followed as that cancer instead. If your report uses the older phrase “invasive implants”, ask your team explicitly which of those two situations you are in.
Borderline tumours are staged with the same FIGO system used for ovarian cancer, and most are stage I. The catch is that a stage cannot be assigned confidently unless the abdomen was actually examined and sampled: washings taken, the omentum biopsied, peritoneal surfaces inspected and biopsied, and the other ovary assessed.
Where a tumour was removed as though it were a simple cyst and only turned out to be borderline afterwards — a common story — the recorded stage is really an assumption. Your team then weighs a second, staging operation against careful surveillance, taking your age, the subtype, the growth pattern and your plans for children into account. That decision belongs at a tumour board, not with one clinician.
The plan is surgical from beginning to end, and the questions that matter are how much surgery, when, and how long the follow-up runs. Two things stay constant — complete staging, and a plan agreed at a tumour board rather than by one clinician.
The affected ovary and tube are removed, along with washings from the abdominal cavity, sampling of the omentum, and biopsies of the peritoneal surfaces. Staging carries unusual weight here, because the entire question of whether you need anything beyond follow-up depends on whether a stage I is genuine or merely unexamined. This surgery is performed by specialist gynaecologic-oncology surgeons at partner centres, coordinated by CION, and may be billed there.
For a younger woman with disease confined to one ovary, removing that ovary and tube — or in selected cases only the cyst itself — while leaving the uterus and the other ovary in place is an established approach, with full staging still carried out. Recurrence is commoner after the more conservative operation, but it is usually borderline disease again and usually treatable by further surgery. Raise it before the operation: see fertility with borderline ovarian tumours.
Where the tumour is mucinous, the appendix is inspected during surgery and removed if it looks abnormal. A mucinous tumour in the ovary can have arrived from the appendix, and that possibility is settled at the operating table rather than assumed away afterwards.
Chemotherapy has no established role in borderline ovarian tumours. These tumours do not invade destructively, they divide slowly, and studies have not shown that adding chemotherapy after complete surgery improves outcomes. Being told that no further treatment is needed can feel like being under-treated. It is not. If a chemotherapy discussion has been raised with you, ask whether the report describes invasive implants or an invasive carcinoma, because that is usually what has changed the conversation. The wider picture is set out in our guide to ovarian cancer treatment in Hyderabad.
Surveillance means clinical examination, pelvic ultrasound where ovarian tissue remains, and a tumour marker if yours was raised at diagnosis. It should continue well beyond the two or three years usual after many cancers, because borderline tumours can recur five, ten or more years after removal. A long follow-up plan is not a sign that anyone is worried; it is the correct management of a slow disease.
Recurrence after fertility-sparing surgery is usually borderline disease again, in the remaining ovary, and is usually managed with further surgery rather than with drugs. A smaller proportion of recurrences are invasive low-grade serous carcinoma, which is then treated as that cancer. This is exactly what the long follow-up is designed to catch, and catching it early is what keeps the options simple.
Staging surgery, debulking surgery, HIPEC and PET-CT are delivered at specialist partner centres and coordinated by CION, and may be billed there. Genetic counselling, nutrition support, long-term follow-up and chemotherapy where it is genuinely indicated are delivered in-house across 35+ centres.
Bring the pathology report and the operation notes. In a borderline tumour those two documents settle almost everything, and five lines in them decide the plan: the subtype, the growth pattern, whether microinvasion was seen, whether implants were found and of what type, and whether the abdomen was actually staged. Women are routinely told the reassuring headline and never the rest — then read material about invasive ovarian cancer and apply it to a disease that behaves nothing like it.
Your first consultation at CION is free and runs to about 45 minutes. Cases that raise a question go to a tumour board with medical oncology, pathology and imaging in the room, which matters here because the commonest genuine dilemma — whether to go back for a staging operation after a cyst turned out to be borderline — has no single right answer. It depends on your age, the subtype, the growth pattern and whether you want children. We will also say plainly when the honest answer is that nothing more is needed than a long follow-up plan.
On borderline ovarian tumour prognosis, the honest position is that the outlook after complete surgery is very good, and that published survival figures still mislead in two directions. They are drawn largely from historical series assembled before the current classification, when invasive implants and some low-grade serous carcinomas were counted as borderline disease. And they are usually reported at five years, far too short a window for a tumour that can return a decade later. What is genuinely established is that most women with a completely staged borderline tumour are cured by surgery alone, and that the main risk is recurrence rather than death. A percentage lifted from a chart will not tell you which pattern is yours.
Surgery for borderline tumours — staging, fertility-sparing operations and any completion surgery later — is coordinated with specialist gynaecologic-oncology partner centres and may be billed there. Genetic counselling, nutrition support, follow-up, and chemotherapy in the uncommon situation where the disease proves invasive, are delivered by CION in-house across 35+ centres. We would rather be straightforward about that division than have you discover it later.
Free, and long enough to go through the report line by line — subtype, growth pattern, microinvasion, implants, and whether staging was complete.
Medical oncology, pathology and imaging review the case together. Where the question is whether to re-operate for staging, a single opinion is not enough.
Surveillance planned in years rather than months, and delivered close to where you live, across 35+ centres in Telangana and Andhra Pradesh.
One-year survival across CION's treated ovarian cancer population against the national figure. It describes invasive disease of every stage and subtype mixed together and says nothing specific about borderline tumours — it is not a cure rate, and not a prediction for you.*
*One-year survival rates. CION figures reflect CION's treated ovarian cancer population across all subtypes and stages; national figures are drawn from published Indian cancer registry data. Survival statistics describe groups, not individuals — discuss your own outlook with your treating oncologist.
Not invasive cancer, and that distinction is real rather than a kindness. Under a microscope the cells have multiplied into layers and look abnormal, but they do not invade and destroy the ovarian tissue around them, which is the defining feature of a carcinoma. Pathologists place borderline tumours in their own category between benign cysts and ovarian cancer, and older reports call them tumours of low malignant potential. Practically, the difference shows in the treatment: surgery removes the disease, chemotherapy has no established role, and most women are cured by the operation alone. Two things still need proper attention. The staging has to be complete, and the follow-up has to be long, because these tumours can return years afterwards.
Very good after complete surgery, and better than most figures you will find written down suggest. Published survival numbers for these tumours mislead in two directions. Most come from historical series collected before the current WHO classification, when deposits now recognised as low-grade serous carcinoma were still counted as borderline disease, which drags the numbers down. And they are usually reported at five years, far too short a window for a tumour that can recur ten or fifteen years later, which flatters them. What is genuinely established is that most women with a completely staged borderline ovarian tumour are cured by surgery alone, and that the main risk is recurrence rather than death from the disease. Ask your team about your own stage, subtype and growth pattern rather than about an average.
No. Chemotherapy has no established role in borderline ovarian tumours at any stage, including where non-invasive implants are present. These tumours do not invade destructively and they divide slowly, and studies have not shown that adding chemotherapy after complete surgery improves outcomes. Being told that no further treatment is needed, after a diagnosis with the word tumour in it, feels wrong to many women, and some ask for chemotherapy to be given anyway. It would add side effects without adding benefit. If chemotherapy has been raised with you, the question to ask is whether the report describes invasive implants or an invasive carcinoma rather than a borderline tumour, because that is usually what has changed the conversation, and it changes the whole plan.
Often, yes, and this is one of the main reasons the diagnosis is handled differently from ovarian cancer. Most borderline tumours occur during the reproductive years and most are confined to one ovary, so removing that ovary and tube, or in selected cases only the cyst, while leaving the uterus and the other ovary in place is an established option with full staging still carried out. Recurrence is commoner after the more conservative operation, but it is usually borderline disease again and usually managed with further surgery. The decision has to be made before the operation rather than after, because the surgery itself determines what remains possible. Our guide to fertility with borderline ovarian tumours covers the options in detail.
It can, though it is not the usual course. A small proportion of borderline tumours, particularly serous ones with a micropapillary pattern, recur as low-grade serous carcinoma rather than as borderline disease, and that recurrence is then treated as a cancer. Most recurrences are borderline again and are managed with surgery. This is the reason follow-up runs for years rather than months, and the reason a discharge at two or three years is worth questioning. It is also why the wording of your original report matters so much: a micropapillary pattern, microinvasion or implants all tip the balance towards closer surveillance, even though none of them changes the diagnosis itself.
It is a common situation and there is no single right answer, which is exactly why it belongs at a tumour board. The difficulty is that a stage cannot be assigned confidently when the abdomen was never examined, so the reassuring stage I on your record may be an assumption rather than a finding. A second operation would take washings, sample the omentum and biopsy the peritoneal surfaces, and would settle the question. Against that sit the surgery itself, your age, your plans for children, and the subtype and growth pattern of the tumour. Some women are staged properly; others are followed closely instead, with the option of completion surgery later. Take the pathology report and the operation notes to that discussion, because the decision turns on what they say.
The first consultation is free and runs to about 45 minutes. For a borderline ovarian tumour, most of what CION offers is review and coordination rather than drug treatment, because the disease is treated surgically and needs no chemotherapy. That means a careful second read of your pathology report and operation notes, a tumour board discussion where the case raises a question, coordination of staging or fertility-sparing surgery with specialist gynaecologic-oncology partner centres, and a long-term follow-up plan delivered across more than 35 centres in Telangana and Andhra Pradesh. Surgery, HIPEC and PET-CT are performed at those partner centres and may be billed there, and we say so upfront. Genetic counselling, nutrition support, and chemotherapy in the uncommon event that the disease proves invasive, are delivered in-house.